1 research outputs found
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naĂŻve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naĂŻve participants after two doses than in Rec after a single dose (pâ<â0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (pâ<â0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.This work is funded by Instituto de Salud Carlos III, a Spanish public body assigned to the Ministry of Science and Innovation that manages and promotes public clinical research related to Public Health, by Grants PI19CIII/00004 (JosĂ© AlcamĂ and Francisco DĂezâFuertes) and PI21CIII/00025 (Javier GarcĂaâPĂ©rez and Mayte PĂ©rezâOlmeda), COVIDâ19 Fund (Grants COV20/00679 (Javier GarcĂaâPĂ©rez, Mayte PĂ©rezâOlmeda, JosĂ© AlcamĂ, and Francisco DĂezâFuertes) and COV20/00072 (Javier GarcĂaâPĂ©rez, Mayte PĂ©rezâOlmeda, Almudena RamĂrezâGarcĂa, MarĂa Castillo de la Osa, Rocio Layunta Acero, Laura VicenteâIzquierdo, Cristina AvendañoâSolĂĄ, and JosĂ© AlcamĂ), and CIBERINFEC, coâfinanced by the European Regional Development Fund (FEDER) âA way to make Europe.âS